Newsletter - Sterling-Hoffman Life Sciences - Jobs and Careers in Pharmaceuticals, Bio Technology, Healthcare and Staffing Firm

To advertise in the Sterling-Hoffman Life Sciences Journal, click here

December 2007

This Month

What can we do for you?
Research:

Impact of Genomics on Medicine

Challenges in Clinical Trial Specimens Testing Laboratory

To Bill or Not to Bill? Will the Revised CRP Answer the Question?

Poll: Is the lack of a national stem cell policy hurting the biotech industry?
Latest Job Openings

What can we do for you?

Want to know about the latest research findings and hottest jobs in the Pharmaceutical and Biotechnology Industry? Then you’ve come to the right place. When you want up-to-the-minute information and job listings for Clinical Research Associates, Contract Clinical Research Associates and Clinical Trial Managers, Sterling-Hoffman Life Sciences Journal is the source to turn to.

"Medicine is a science of uncertainty and an art of probability."

- William Osler (Physician, Father of Modern Medicine, 1849-1919)

Impact of Genomics on Medicine

By Jingfang Ju, Ph.D., Head, Cancer Genomics Laboratory Mitchell Cancer Institute, University of South Alabama

Human disease is quite complex. In the case of cancer, it is not a single genetic disease but, rather, hundreds of diseases consisting of various combinations of genetic alterations. However, through the development of genomics, personalized medicine can become a reality in the new millennium. The impact of genomics on drug target discovery, drug development, and biomarker-based therapy tailored to an individual’s unique genetic background will be enormous, allowing everyone to benefit from it.

Read full article

Challenges in Clinical Trial Specimens Testing Laboratory

By Rishab K. Gupta, Ph. D., Professor Emeritus, Division of Oncology, Department of Surgery, and David Geffen School of Medicine at UCLA and Past Director of Research Core Services, and Immunodiagnosis & Protein Biochemistry, John Wayne Cancer Instit

The main goal in any medical investigation is to discover effective therapeutic agents and validate their effectiveness through clinical trials. These trials involve a large number of subjects in all arms of the trial to assess statistical significance of clinical outcome in response to the therapeutic agent. To achieve the clinical outcome as an endpoint, the trials are lengthy and expensive. It is highly appropriate to take advantage of these trials to incorporate possible surrogate biomarkers to identify which markers are reliable for early detection of disease.

Read full article

To Bill or Not to Bill? Will the Revised CRP Answer the Question?

By Wendy Schroeder, RN, CCRC, Banner Health Research Institute

Navigating the patient care services billing path can be tricky when conducting a clinical research study. It is not always clear as to which patient care services can be billed and which can't. Will revisions to the CRP help answer the question: To bill or not to bill patient care items and services in the context of a clinical trial?

Read full article

Is the lack of a national stem cell policy hurting the biotech industry?